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Poster Session I S301nutrition. Red cell requirement was\ 4 units in 9 children and . 4
units in 11 children. Platelet support was required\5 in 5 children
and. 5 in 15 children. Two of the eighteen children did not engraft
and 4 children had graft versus host disease and 1 child died on day 10
due to acute cardiomyopathy. Two children had mild sinusoidal ob-
struction syndrome. Group two had 9 class I, 3 class II and 8 class III
patients between age groups 1 to 13 years. Mucositis was grade two
and above in 5 children and they needed partial parenteral nutrition.
Less than 4 units of red cells were required in 15 children and . 4
units in 5 children. Platelet support was required on less than occa-
sions in 10 children and . 5 in 10 children. All of the eighteen chil-
dren engrafted and 2 children had graft versus host disease. There
was no mortality and two children had early graft rejection before
day 100. No child had sinusoidal obstruction syndrome.
We conclude that this treosulphan based regimen is well tolerated
and results in durable engraftment even in Class III thalassaemia ma-
jor children with no major toxicity or mortality.
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PULMONARY ARTERYOPATHY AND PULMONARY HYPERTENSION FOL-
LOWING TANDEMAUTOLOGOUS TRANSPLANTS IN PEDIATRIC PATIENTS
WITH CNS TUMORS
Schechter, T.1, Leucht, S.1, Bouffet, E.1, Cutz, E.2,Gassas, A.1,Huang,A.1,
Bartels, U.1, Humpl, T.3, Doyle, J.1 1The Hospital for Sick Children,
Toronto, ON, Canada; 2The Hospital for Sick Children, Toronto, ON,
Canada; 3The Hospital for Sick Children, Toronto, ON, Canada
Introduction: Young children with central nervous system (CNS)
tumors are frequently being treated with tandem cycles of high
dose chemotherapy followed by autologous stem-cell transplants in
an attempt to avoid cranial irradiation. The most common combina-
tions of chemotherapy used is carboplatinum and thiotepa. Though,
multiple side effects were documented, pulmonary arteriopathy
leading to pulmonary hypertension (PH) was not previously docu-
mented in patients treated for primary CNS disease. We herein re-
port PH as a complication post autologous transplantation using
carboplatinum and thiotepa as conditioning therapy.
Methods: A retrospective evaluation of all pediatric patients diag-
nosed with primary CNS tumors between 2001-2010 who were
scheduled to be treated with 3 cycles of high dose chemotherapy
with carboplatinum (17mg/kd/day for 2 days) and thiotepa (10mg/
kg/day for 2 days) followed by autologous stem-cell transplants
was conducted. The primary objective was to evaluate the incidence
of PH in this population and patients’ outcome following the devel-
opment of PH.
Results: 14 patients were scheduled to received 3 cycles of autolo-
gous transplantation. The median age was 28 months (range
3-41months). Patients’ diagnoses were: atypical teratoid rhabdoid
tumor – 8 patients, medulloblastoma- 4 patients and primitive neu-
roectodermal tumor- 2 patients. Three patients developed biopsy
confirmed pulmonary arteriopathy. The two patients that developed
echocardiographic evidence of PH after the third cycle of high dose
therapy succumbed to right heart failure, while one patient who’s PH
was detected after the second cycle didn’t receive the third cycle and
survived this complication. The overall survival (OS) of the 14 pa-
tients was 0.48 +/- 0.15 at a median of 14.32 months (range 4.99-
68.21 months). Death from progression was 0.43 +/- 0.16 and
non-relapsed mortality was 0.15 +/- 0.10. The 2 patients who died
from PH represented the only non-relapsed mortality in our cohort.
Conclusions: Pulmonary hypertension is a major complication fol-
lowing high dose chemotherapy and autologous transplantation with
a high likelihood of mortality despite PH directed therapy. Echocar-
diographic evaluation of the right ventricle and screening specifically
for PH should be included after each cycle of high dose chemother-
apy in pediatric CNS tumor population. Consideration for longer
interval between cycles should be done to allow proper follow-up be-
tween cycles.
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OUTCOMES OF HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR
INHERITED METABOLIC DISORDERS: A REPORT FROM ANZCHOG AND
ABMTRR
Mitchell, R.1, Smith, Nivison-I.2, Teidemann, K.3, Mechinaud, F.3,
Shaw, P.J.4, Teague, L.5, Fraser, C.6, Tapp, H.7, Cole, C.H.8,Alvaro, F.9, O’Brien, T.A.1 1Sydney Children’s Hospital, Sydney, Aus-
tralia; 2Australasian Bone Marrow Transplant Recipient Registry, Syd-
ney, Australia; 3Royal Children’s Hospital, Melbourne, Australia;
4Children’s Hospital Westmead, Sydney, Australia; 5Starship Children’s
Hospital, Auckland, New Zealand; 6Royal Children’s Hospital, Brisbane,
Australia; 7Women and Children’s Hospital, Adelaide, Australia; 8Prin-
cess Margaret Hospital for Children, Perth, Australia; 9John Hunter
Children’s Hospital, Newcastle, Australia
We report a retrospective analysis of 53 haematopoietic stem cell
transplants for inherited metabolic disorders performed at Australia
and New Zealand Children’s Haematology Oncology Group
(ANZCHOG) transplant centres between 1992 and 2008. The
most common indications for transplant were Hurler syndrome
(47%), adrenoleukodystrophy (ALD) (28%) and metachromatic
leukodystrophy (17%). The median age of patients was 2 years
(0-15). 11 (32%) patients received marrow from matched siblings,
1 from an HLA-identical parent. The remaining 66% received
grafts from unrelated donors, with 22 (42%) using single UCB,
13 BM or PBSC (23%) and one double UCB transplant. 55% of pa-
tients received Busulphan and Cyclophosphamide as their condi-
tioning regimen, and 34% received Bu/Cy + Other (Melphalan or
Fludarabine). 54% had in-vivo T cell depletion using ATG or
Campath, and 15% had ex-vivo T cell depletion. Median time to
neutrophil and platelet engraftment was 16 and 35 days respec-
tively, with a cumulative incidence (CI) at day +42 of 94% and
73% respectively. There were 3 graft failures, all engrafted after
a second URD, and are alive at 10, 5 and 3 years post transplant.
The CI of aGVHD grade II-IV and III-IV at day +100 was 39%
and 14% respectively. 17% of patients had cGVHD at 1 year
post transplant. Transplant related mortality (TRM) was 12% at
day +100, and 19% at 1 year post transplant. Overall 5 year survival
(OS) was 78% for the cohort, with 73% for ALD and 83% for
Hurler syndrome. There were no late deaths reported for the co-
hort, with median follow up of 4 years. Neither age, year of trans-
plant, donor source, or HLA match impacted OS. In contrast, the
development of interstitial pneumonitis was the only significant var-
iable associated with an increase in TRM and decrease in OS. This
is keeping with previously reported literature for this patient co-
hort1. In summary, we report excellent OS in a large cohort of pa-
tients transplanted for a range of metabolic disorders.
1. Orchard PJ,Milla C, Braulin E et al. ‘‘Pre-transplant risk factors
affecting outcome in Hurler syndrome’’ Bone marrow transplant.
(2010) 45: 1239-1246.263
CHEMOTHERAPY-ONLY PREPARATIVE REGIMEN FOR ALTERNATIVE DO-
NOR HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS
WITH FANCONI ANEMIA
Mehta, P.A.1, Davies, S.M.1, Duncan, C.2, Guinan, E.2, Klein, E.4,
Edwards, S.1, Lehmann, L.2, Margolis, D.3, Williams, D.2, Boulad, F.4
1Cincinnati Children’s Hospital Medical Center, OH; 2Boston Children’s
Hospital, MA; 3Children’s Hospital of Wisconsin, WI; 4Memorial Sloan-
Kettering Hospital, NY
Background: A significant number of patients with Fanconi anemia
(FA) who survive hematopoietic stem cell transplantation (HSCT),
develop solid tumors. The relative contributions of total body irradi-
ation (TBI) and chronic graft vs. host disease (GvHD) to the devel-
opment of tumors are unknown. Our study aims to examine whether
non-TBI based preparative regimen improves alternative donor
HSCToutcome in FA.Here we report results of our interim analysis
after first 17 patients.
Methods: Seventeen patients were enrolled in this phase II multi-
center protocol between June 2009 and October 2011. See Table 1
for patient and donor characteristics. Preparative regimen in-
cluded: Busulfan 0.8-1.0 mg/Kg/dose Q 12H x 4 doses (D-7&-6),
Cyclophosphamide 10 mg/Kg/day, Fludarabine 35 mg/m2/day and
Rabbit ATG 2.5 mg/Kg/day x 4 days (D-5 to D-2).GvHD pro-
phylaxis was cyclosporine starting D-2. Filgrastim was used starting
D+1. Busulfan doses were adjusted to keep the steady state con-
centration low in most cases. All grafts were T-cell depleted using
the CliniMacs CD34 columns (Miltenyi). Cell doses of the grafts
were: 4.9 -42.7 x 106 CD34 cells/Kg and 2.24- 49.90 x 103 CD3
cells/Kg.
S302 Poster Session IResults: Sixteen of 17 evaluable patients have engrafted (one is too
early to evaluate). Early toxicity data is available for 16 patients
and include: oral mucositis (maximum grade 3), hypertension (max-
imum grade 3), and hyperbilirubinemia (N5 3). One patient devel-
oped hepatic veno-occlusive disease, after which the busulfan goal
level on pharmacokinetic analysis was reduced to keep a lower steady
state concentration target. After this adjustment, there have been no
further occurrences of VOD. Infections included: CMV viremia
(N 5 2), influenza A (N 5 1), clostridium difficile (N 5 1), bacter-
emia (N 5 1) and clostridium botulinum (N 5 1). To date, 14 of
the 17 patients are alive and disease-free at a median follow up of 6
months (range 0.3 – 28months). Cause of death for the three patients
was multi-organ failure (N 5 1), infection (N 5 1), and severe pul-
monary hypertension (N 5 1).
Table 1. Patient and donor characteristics
Characteristics Number or Median (Range)Table 1.
Patients tested (n)
Overall prevalence (n;%) 23/63 (3
Viremia only (n;%) 5/63 (8
Invasive disease (n;%) 6/63 (1
Stoll only (n;%) 11/63 (1
Median viral load (copies/ml) 2,189 (6Patients
Total no. of patients 17
Males 9
Females 8
Age (years) 8 (5-27)
Transplant indication
Severe Single lineage cytopenia 2
Aplastic anemia 12
MDS - refractory anemia 2
refractory anemia with excess blasts 1
Prior treatments
Transfusions 16
Androgens 8
Prior infections 6
Donors
Related 5
(parental 8/8, 6/8, 5/8 (N 5 2) and 4/8
matched donors)
Unrelated 12
(8/8 matched n5 11 and 7/8 matched N5 1)Conclusion: In this interim study report, engraftment, early toxicity
and infection data appear to be similar to historical TBI-based pro-
tocols with no graft failures to date. Although the study is ongoing
with planned accrual of 25 total patients, these results appear prom-
ising and suggest that such alternative donor HSCT can be effec-
tively performed without radiation.
264
VIRAL INFECTIONS IN CHILDREN UNDERGOING AUTOLOGOUS HEMATO-
POIETIC STEM CELL TRANSPLANTATION
Ozdemir, N., Grimley, M.S., Davies, S.M., Myers, K.C., Mehta, P.A.,
Bleesing, J.J., Jordan, M.B., Marsh, R.A., Kumar, A.R.,
Filipovich, A.H., Jodele, S. Cincinnati Children’s Hospital Medical Cen-
ter, Cincinnati, OH
Background: Viral infections are a known cause of morbidity and
mortality in patients receiving allogenic hematopoietic stem cell
transplantation (SCT), however limited data has been reported in
pediatric patients undergoing autologous transplant. The aim of
this retrospective study was to evaluate the prevalence and outcomeAD V CM
63 63
5%) 6/63 (10%
%) 3/63 (5%)
0%) 3/63 (5%)
7%) 0
45-142,300) 15,567 (2,66of viral infections in children undergoing autologous SCT
(auto-SCT).
Methods: Between January 2004 and July 2011 a total of 140 autol-
ogous transplants were performed for malignant diseases in 90
patients. Patients who were seropositive for cytomegalovirus
(CMV) or Epstein-Barr virus (EBV) were monitored with blood
polymerase chain reaction (PCR) weekly. Adenovirus (ADV) weekly
blood monitoring by PCR was initiated in 2007. Polyoma BK virus
(BKV) virus testing was done as clinically indicated for hematuria
and if positive, monitoring for viremia was initiated. Viremia was de-
fined as the presence of virus in blood above detectable level on quan-
titative PCR. Invasive disease was defined as virus detection at least
in two different organ systems. Patients with hypogammaglobulin-
emia received intravenous immunoglobulin supplementation to
maintain nornal for age IGG level.
Results: Sixty four of 90 patients were tested for viruses. Twenty
nine of the tested patients had viruses detected, with 10 patients hav-
ing more than one virus. Table 1 summarizes the prevalence of vi-
remia and viral infections. Most prevelant virus was adenovirus,
presenting as either enteritis or invasive disease. CMV or EBV
pneumonitis was diagnosed in 3 symptomatic patients. Three pa-
tients developed virus-associated thrombotic microangiopathy re-
sulting in renal failure in 2 patients. Viral infection was a cause of
death in 2% (2/90) of all patients undergoing auto-SCT or in 3%
(2/64) of patients who were tested for viruses.
Conclusion: In our patient cohort serious viral infections were rare.
Even in the presence of invasive disease mortality was low. Data sug-
gests that routine viral screening is not neccesary for all patients un-
dergoing auto-SCT, however symptomatic patients should be
evaluated promptly.265
FAMILIAL HAPLOIDENTICAL (FHI) T-CELL DEPLETED (TCD) TRANS-
PLANTATION IN HIGH-RISK SICKLE CELL DISEASE (IND 14359)
Radhakrishnan, K.1, Talano, J.-A.2, Keever-Taylor, C.2, Bhatia, M.3,
Shenoy, S.4, Walters, M.5, Parsons, S.6, Morris, E.1, Baxter-
Lowe, L.A.7, Cairo, M.S.1 1New York Medical College, Valhalla, NY;
2Medical College of Wisconsin, Milwaukee, WI; 3Columbia University,
New York, NY; 4Washington University, St. Louis, MO; 5Children’s
Hospital & Research Center, Oakland, CA; 6TuftsMedical Center, Boston,
MA; 7University of California at San Francisco, San Francisco, CA
Background: Stem cell transplantation has been highly successful
for poor-risk SCD but only 14-18% of patients have an HLA-
matched unaffected sibling (Bhatia/Walters, BMT, 2008). Alternate
allogeneic donors include unrelated adult donors and unrelated cord
blood donors (Cairo et al., BBMT, 2008). Due to patient demo-
graphics matched unrelated adult donors are limited in the registries
and results of unrelated UCB transplants have been dismal to date.
(Bhatia/Cairo et al., ASBMT, 2010 and CTN 0601)
FHI TCD AlloSCT is an alternative that could greatly improve
outcomes in these patients. A recent phase II trial in high-risk leuke-
mia patients utilized CliniMACS (Miltenyi Biotec) one step CD34+
selection, and demonstrated a median recovery of CD34+ cells of
79%, median T-cell depletion of 4.5log, 94/101 patients engrafted
with aGVHD in only 8/100 patients. (Aversa et al.,JCO, 2005) Min-
imal-intensity conditioning followed by FHI TCD in high risk thal-
assemia patients achieved engraftment in 16/22 patients without
aGVHD and 90% OS. (Sodani et al., Blood, 2010)
Objective: This study seeks to employ a similar approach in high-
risk SCD patients.V EBV BK
58 5
) 9/58 (16%) 2/5 (40%)
6/58 (10%) 0
2/58 (3%) 2/5 (40%)
1/58 (2%) 0
5-61,600) 1,302 (647-7,207) 125,540 (50,520-44x10^6)
